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Donna K. Arnett, MSPH, PHDW orldwide, an estimated 1.5 million deathswere caused by diabetes mellitus in 2012(1), up from 1 million in 2000. Diabetes
has been shown to be associated with a 2-fold
increased risk of all-cause mortality and a 3-fold
increased risk of cardiovascular disease mortality
relative to age- and sex-matched controls in a
contemporary primary care population in the United
Kingdom (2). Blood pressure (BP) and diabetes share
common mediators, including inﬂammation and
endothelial dysfunction (3). Despite the known rela-
tionships between BP and diabetes, evidence sup-
porting a clear population-level association between
increased BP and the development of new-onset dia-
betes has been mixed. Large national databases of
electronic medical records and meta-analytical tech-
niques represent 2 possible routes to elucidate the
strength of an association, if not a causal relationship,
between BP and incident diabetes.SEE PAGE 1552In this issue of the Journal, Emdin et al. (4) evaluate
the association between BP and the risk of incident
diabetes in a cohort of 4.1 million adults. Making use
of electronic medical records, this study included data
from patients 30 to 90 years of age without diabetes;
exclusion criteria included prevalent renal disease,
peripheral vascular disease, heart failure, cerebro-
vascular disease, ischemic heart disease, and type 1 or
type 2 diabetes. Data were collected from the U.K.*Editorials published in the Journal of the American College of Cardiology
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about 9% of the U.K. population, and the Hospital
Episode Statistics database, which includes data on
hospital admissions, outpatient appointments, and
cause-speciﬁc mortality for hospital events. BP mea-
surements made between January 1990 and January
2013 were adjusted for regression-dilution bias
(a downward bias of the association regression slope
resulting from measurement error and unaccounted
for variability in BP [5]) by regressing serial BP mea-
surements on a baseline measurement. Hazard ratios
for measured BP (adjusted for age, sex, and body
mass index [BMI], smoking status within 2 years of
baseline, and baseline antihypertensive and lipid-
lowering drug use) were multiplied by regression
dilution ratios of 2.1 and 2.5 for systolic BP (SBP) and
diastolic BP (DBP), respectively, to estimate incident
diabetes associations with “usual” BP.
The primary outcome was deﬁned as a diagnosis of
type 2 or unspeciﬁed diabetes or issuance of a pre-
scription for insulin or an antidiabetic drug. Partici-
pants were censored at ﬁrst occurrence of the primary
outcome. A series of 6 sensitivity analyses were
performed to evaluate impact of various covariate
adjustments including cholesterol, lipid, and hyper-
tension treatments, cohort effects (adjusting for
timing of initial BP measurement), diabetes deﬁnition
(as listed previously vs. excluding those with un-
speciﬁed diabetes), and timing of events (events in all
years vs. excluding events in years 1, 2, and 4).
The authors also conducted a random-effects
meta-analysis of prospective observational studies
of BP and incident diabetes. This analysis included
ﬁndings from 30 studies enlisting 285,664 partici-
pants with 17,388 incident diabetes events. Regres-
sion dilution ratios generated in the main study were
applied in the meta-analysis.
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1564In the primary analysis, about 60% of the partici-
pants were women, median age was 46 years, median
BMI was 25.7 kg/m2, and median follow-up was
6.8 years. A total of 186,698 participants met the
deﬁnition of the primary outcome. Emdin et al. (4)
reported that, overall, a 20 mm Hg increase in SBP
and a 10 mm Hg increase in DBP were associated with
a 58% (95% conﬁdence interval [CI]: 1.56 to 1.59) and
52% (95% CI: 1.51 to 1.54) increase in the risk of new
diabetes, respectively. For SBP, the association was
strongest for those with normal or slightly elevated
usual pressures with a ﬂattening of the curve below
and above the SBP extremes (about 110 and
150 mm Hg, respectively). Diastolic BP was similarly
associated with the onset of diabetes but with less
evidence for plateaus toward the extremes (70 and
100 mm Hg). The associations were modiﬁed by sex
(stronger associations observed in men), but not at
clinically meaningful differences. Baseline BMI and
age more strongly modiﬁed the association: lower
BMI and younger age exhibited greater relative risk
increases with increasing BP (although because of
differences in baseline risk, absolute risk increases in
the higher BMI and older strata were equal to or
higher than increases in absolute risk in lower BMI
and younger strata). For example, for those with
BMI <25 kg/m2, the hazard ratio for a 20 mm Hg in-
crease in SBP was 1.89 (95% CI: 1.84 to 1.94); for those
with BMI >35 kg/m2, the hazard ratio was 1.19
(95% CI: 1.16 to 1.22). In analyses in which subjects on
antihypertensive or lipid-lowering drugs were
excluded, risk estimates were similar to those made
in the full cohort. In the meta-analysis, the pooled
relative risk for each 20 mm Hg higher usual SBP was
1.77 (95% CI: 1.53 to 2.06).
These ﬁndings support a longstanding hypothesis
(6) regarding the association between BP and the risk
of diabetes. This well-designed study illustrates the
utility of carefully collected and appropriately
analyzed electronic medical records from practice
databases. The consistency of ﬁndings between the 2
approaches also adds value to the association ﬁndings.
Several elements of the Emdin et al. (4) study are
worthy of further consideration. For example, the
regression dilution ratios of 2.1 (SBP) and 2.5 (DBP),
used to derive usual BP in this study, are considerably
higher than those in the range of 0.40 to 0.56
employed in a number of large cohort studies inEurope and the United States (7). These differences
were not explored, and, if the ratios used in Emdin
et al. (4) are elevated, this overcorrection would have
inﬂated hazard estimates of diabetes with increased
BP in both the primary study and the meta-analysis.
Emdin et al. (4) reported that the prevalence of
antihypertensive drug use during follow-up was
considerably higher among those with higher base-
line usual BP: 52.2% among those with SBP >136
mm Hg versus 13.0% among those with SBP <127
mm Hg at baseline. The authors, however, made no
adjustment for the type of antihypertensive treat-
ment. It is well-documented that thiazide diuretics
are associated with a greater incidence of diabetes.
For example, in the ALLHAT (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack
Trial) participants without metabolic syndrome, dia-
betes occurred in 7.7% in the chlorthalidone treat-
ment arm versus 4.2% and 4.7% in the amlodipine
and lisinopril arms, respectively (8). Although the
sensitivity analyses done by these authors temper
concern over confounding by type of antihyperten-
sive treatment, this complication of the clinical pic-
ture is worthy of further exploration.
Although Emdin et al. (4) ﬁndings may bolster
evidence for an existing hypothesis, they are unlikely
to motivate any changes in clinical practice. Associ-
ation studies simply identify clinical correlates; they
do not provide insights into the mechanisms that
could contribute to the observed ﬁndings. Although
the authors postulate that increased inﬂammation is
the culprit, other metabolic or biochemical mediators
may be the driving force leading to diabetes. None-
theless, these investigators offer an exceptionally
rigorous evaluation of the relation between BP and
incident diabetes, including well-powered analyses
of subgroups. Their methods make superb use of large
clinical databases and their complementary meta-
analysis provides further support of the association.
This study provides a strong rationale for continued
research into the biological basis and pharmacological
implications of the observed association.
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